Wednesday, May 15, 2019

ImmunoGen's Mirvetuximab isn't dead yet

The Phase III trial of Immunogens Mirvetuximab failed to meet its primary endpoints.  However, that does not mean complete and total death.  It looks like they are continuing to discuss with the FDA and another clinical trial is going to be in the works.

ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer

Hopefully the completion of this trial will lead to success for them, and for the market as a whole.

By
Labels: , ,

1 comment:

  1. loqfpdy6emJanuary 13, 2023 at 8:53 PM

    Responsible gaming packages are an excellent start, but placing too much amount of} of the onus on the player to gamble safely is not going to be sufficient to assure lawmakers and the public public} that the trade is being proactive. Download the app and might be} presented with the online on line casino registration page. Lottery’s agreement with Draft Kings offers the state 51% of gross gaming income from on-line wagering and 50% of GGR from retail wagers. Sports betting tax income goes towards of|in course of} funding the implementation of the state water 안전놀이터 plan and different public functions. When creating your account, don’t overlook to make use of your sign-up bonus code This will unlock the beneficiant new player supply which you are be} entitled to.

    ReplyDelete

Subscribe to: Post Comments (Atom)